A similar inhibitory effect of miR-135a was revealed in pancreatic cancer by its targeting of Bmi-128 and in gallbladder cancer by its targeting of very low density lipoprotein receptor (VLDLR); the p38 MAPK pathway is the downstream signaling pathway of miR-135a-VLDLR36. This evidence concerns the gene VLDLR and familial pancreatic carcinoma.